

FEDERAL REGISTER INDEX

January–March 2015

Food and Drug Administration

RULES

Banned Devices; CFR Correction – 11865 (Mar 5)

Guidance for Industry and Staff:

Individual Patient Expanded Access Applications – 7318 (Feb 10)

Medical Device Reporting:

Electronic Submission Requirements; Correcting Amendments – 10586 (Feb 27)

Medical Devices:

Obstetrical and Gynecological Devices; Classification of the Assisted Reproduction Embryo Image Assessment System – 10330 (Feb 26)

Physical Medicine Devices; Powered Exoskeleton; Classification – 9600 (Feb 24)

Premarket Approvals:

Automated External Defibrillator Systems; Requirement Effective Date – 4783 (Jan 29)

Automated External Defibrillator Systems; Requirement Effective Date; Republication – 5674 (Feb 3)

PROPOSED RULES

Color Additive Petitions:

Signature Brands, LLC – 6468 (Feb 5)

Environmental Impact Statements; Availability, etc.:

Standards for Growing, Harvesting, Packing, and Holding of Produce for Human Consumption – 1852 (Jan 14)

Food Additive Petitions (Animal Use):

Humic Products Trade Association – 422 (Jan 6)

Generic Drug User Fee Amendments; Regulatory Science Initiatives; Public Hearing – 11966 (Mar 5)

Guidance for Industry and Staff:

Standards for Growing, Harvesting, Packing, and Holding of Produce for Human Consumption; Notice for Public Meeting on Draft Environmental Impact Statement – 1478 (Jan 12)

New Drug Applications:

Abbreviated New Drug Applications, etc. – 6801 (Feb 6)

Over-the-Counter Sunscreen Drug Products:

Status of Ecamsule – 10035 (Feb 25)

Status of Enzacamene – 10026 (Feb 25)

Standards for Growing, Harvesting, Packing, and Holding of Produce for Human Consumption:

Environmental Impact Statements; Meeting – 1855 (Jan 14)

Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products:

Meeting; Request for Comments; Reopening of Comment Period – 8577 (Feb 18)

NOTICES

Agency Information Collection Activities; Proposals, Submissions, and Approvals:

Appeals of Science-Based Decisions Above the Division Level at the Center for Veterinary Medicine – 4931 (Jan 29)

Biosimilars User Fee Cover Sheet – 4272 (Jan 27)

Blood Establishment Registration and Product Listing – 4932 (Jan 29)

Class II Special Controls Guidance Document--Labeling of Natural Rubber Latex Condoms – 4273 (Jan 27)

Class II Special Controls Guidance Document; Automated Blood Cell Separator Device Operating by Centrifugal or Filtration Principle – 4927 (Jan 29)

Current Good Manufacturing Practice Regulations for Finished Pharmaceuticals – 10117 (Feb 25)

Current Good Manufacturing Practices and Related Regulations for Blood and Blood Components, etc. – 11444 (Mar 3)

Demonstrating Substantial Equivalence for Tobacco Products and Demonstrating the Substantial Equivalence of a New Tobacco Product -- Responses to Frequently Asked Questions – 11989 (Mar 5)

Disclosure Regarding Additional Risks in Direct-to-Consumer Prescription Drug Television Advertisements – 1637 (Jan 13)

Export of Food and Drug Administration Regulated Products -- Export Certificates – 6728 (Feb 6)

Export of Food and Drug Administration Regulated Products; Export Certificates; Correction – 8087 (Feb 13)

Extralabel Drug Use in Animals – 3607 (Jan 23)

Food and Cosmetic Export Certificate Application Process – 1422 (Jan 9)

Food and Drug Administration Recall Regulations – 7609 (Feb 11)

General Licensing Provisions; Section 351(k) Biosimilar Applications – 5761 (Feb 3)

Guidance for Industry on Postmarketing Adverse Event Reporting for Medical Products, etc., During an Influenza Epidemic – 508 (Jan 6)

Guidance on Consultation Procedures -- Foods Derived From New Plant Varieties – 8663 (Feb 18)

Investigational New Drug Applications – 11449 (Mar 3)

Labeling for Human Prescription Drug and Biological Products; Requirements on Content and Format – 2943 (Jan 21)

Medical Device Labeling Regulations – 4928 (Jan 29)

Multicultural Youth Tobacco Prevention Campaigns – 230 (Jan 5)

Notification of a Health Claim or Nutrient Content Claim Based on an Authoritative Statement of a Scientific Body – 11443 (Mar 3)

Premarket Notification for a New Dietary Ingredient – 10121 (Feb 25)

Prescription Drug Marketing Act of 1987; Administrative Procedures, Policies, and Requirements – 10697 (Feb 27)

Reporting and Recordkeeping Requirements for Human Food and Cosmetics – 1507 (Jan 12)

Substantiation for Dietary Supplement Claims Made under the Federal Food, Drug, and Cosmetic Act – 7610 (Feb 11)

Waiver of In Vivo Demonstration of Bioequivalence of Animal Drugs in Soluble Powder Oral Dosage Form Products, etc. – 1506 (Jan 12)

Biologics Licenses:

CHEMBIOMED, LTD., Opportunity for Hearing on Proposal to Revoke U.S. License No. 0916 – 1917 (Jan 14)

Charter Renewals:

Advisory Committees – 7871 (Feb 12)

Debarment Orders:

Douglas M. Hargrave – 11995 (Mar 5)

Hung Yi Lin – 8664 (Feb 18)

Jeffrey L. Rockmore – 11991 (Mar 5)

John D. Noonan – 12007 (Mar 5)

Steven M. Lynch – 12013 (Mar 5)

William F. DeLuca, Jr. – 12011 (Mar 5)

Determinations that Products Were Not Withdrawn from Sale for Reasons of Safety or Effectiveness:

REYATAZ; Atazanavir Sulfate Capsules, 100 Milligrams – 509 (Jan 6)

SUBUTEX (Buprenorphine Hydrochloride) Sublingual Tablets, Equivalent 2 and 8 Milligrams Base – 8088 (Feb 13)

TAGAMET (Cimetidine) Tablets – 1423 (Jan 9)

Food and Drug Administration Modernization Act:

List of Recognized Standards, Recognition List Number 038; Modifications – 4274 (Jan 27)

Guidance for Industry and Staff:

Adverse Event Reporting for Outsourcing Facilities; Federal Food, Drug, and Cosmetic Act – 8872 (Feb 19)

Advice about Eating Fish; Comment Period Closure – 9732 (Feb 24)

Alcoholism; Developing Drugs for Treatment – 7871 (Feb 12)

Complicated Intra-Abdominal Infections-Developing Drugs for Treatment – 7479 (Feb 10)

Complicated Urinary Tract Infections - Developing Drugs for Treatment – 8325 (Feb 17)

Consumer-Directed Print Advertisements and Promotional Labeling for Human Prescription Drugs – 6998 (Feb 9)

Current Good Manufacturing Practice Requirements for Combination Products – 4280 (Jan 27)

Food and Drug Administration

- Effectiveness of New Animal Drugs for the Reduction of Pathogenic Shiga Toxin-Producing *Escherichia coli* in Cattle; Availability – 9731 (Feb 24)
- Entities Considering whether to Register as Outsourcing Facilities – 8871 (Feb 19)
- Evaluating Drug Effects on the Ability to Operate a Motor Vehicle – 2432 (Jan 16)
- General Wellness; Policy for Low Risk Devices – 2712 (Jan 20)
- In Vitro Diagnostic Devices for Detection of Ebola Virus; Emergency Use Authorizations – 6972 (Feb 9)
- International Conference on Harmonisation; S10 Photosafety Evaluation of Pharmaceuticals – 4282 (Jan 27)
- Investigating and Reporting Adverse Reactions Related to Human Cells, Tissues, and Cellular and Tissue-Based Products – 9267 (Feb 20)
- Laser Illuminated Projectors; Classification and Requirements – 8665 (Feb 18)
- Medical Device Accessories; Defining Accessories and Classification Pathway for New Accessory Types – 2710 (Jan 20)
- Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communication Devices; Mobile Medical Applications – 6996 (Feb 9)
- Medical Device User Fee and Modernization Act – 1424 (Jan 9)
- Medical Devices and Clinical Trial Design for the Treatment or Improvement in the Appearance of Fungally-Infected Nails – 4281 (Jan 27)
- Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products between the States and the Food and Drug Administration – 8874 (Feb 19)
- Mitigating the Risk of Cross-Contamination from Valves and Accessories Used for Irrigation Through Flexible Gastrointestinal Endoscopes – 2711 (Jan 20)
- Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application – 8881 (Feb 19)
- Postmarketing Adverse Event Reporting for Nonprescription Human Drug Products Marketed without an Approved Application – 3608 (Jan 23)
- Premarket Studies of Implantable Minimally Invasive Glaucoma Surgical Devices – 7614 (Feb 11)
- Questions and Answers Regarding Effect of Patient Protection and Affordable Care Act on State and Local Menu and Vending Machine Labeling Laws; Withdrawal – 6996 (Feb 9)
- Repackaging of Certain Human Drug Products by Pharmacies and Outsourcing Facilities – 8884 (Feb 19)
- Safety Considerations to Mitigate the Risks of Misconnections with Small-Bore Connectors Intended for Enteral Applications – 7612 (Feb 11)
- Study Data Technical Conformance Guide and Data Standards Catalog – 1508 (Jan 12)
- Sunscreen Feedback Letters – 892 (Jan 7)
- Technical Performance Assessment of Digital Pathology Whole Slide Imaging Devices – 10122 (Feb 25)
- Training Program for Regulatory Project Managers – 6731 (Feb 6)
- Guidance:
- Clinical Trial Imaging Endpoint Process Standards – 11998 (Mar 5)
 - Demonstrating the Substantial Equivalence of a New Tobacco Product -- Responses to Frequently Asked Questions – 12011 (Mar 5)
- Identifying Potential Biomarkers for Qualification and Describing Contexts of Use to Address Areas Important to Drug Development – 8089 (Feb 13)
- International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs:
- Scheduling Recommendations; AH-7921; Gamma-Butyrolactone; 1,4-Butanediol; Ketamine; 9 Additional Substances – 4283 (Jan 27)
- Medical Devices:
- Safety and Effectiveness Summaries for Premarket Approval Applications – 7615 (Feb 11)
- Meetings:
- Anesthetic and Analgesic Drug Products Advisory Committee – 6731 (Feb 6)
 - Anesthetic and Analgesic Drug Products Advisory Committee; Corrections – 9733 (Feb 24)
- Arthritis Advisory Committee – 7480 (Feb 10)
- Cardiovascular and Renal Drugs Advisory Committee – 10700 (Feb 27)
- Cellular, Tissue and Gene Therapies Advisory Committee, Oncologic Drug Advisory Committee – 7872 (Feb 12)
- Clinical Outcomes Assessment Development and Implementation -- Opportunities and Challenges; Public Workshops – 12010 (Mar 5)
- Clinical Trial Requirements, Regulations, Compliance and Good Clinical Practice – 8325 (Feb 17)
- Conditional Approval of New Animal Drugs – 8091 (Feb 13)
- Dermatologic and Ophthalmic Drugs Advisory Committee – 3969 (Jan 26)
- Dermatologic and Ophthalmic Drugs Advisory Committee and Ophthalmic Devices Panel of the Medical Devices Advisory Committee – 4578 (Jan 28)
- Endocrinologic and Metabolic Drugs Advisory Committee – 11680 (Mar 4)
- Evaluating and Modernizing our Approaches for Food-Effect Assessment; Cosponsored Workshop – 4288 (Jan 27)
- Food and Drug Administration/Xavier University Global Medical Device – 8327 (Feb 17)
- Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics; Public Workshop – 4933 (Jan 29)
- In Motion - Science Transforming Policy in Food, Drug, and Medical Device Regulation – 8328 (Feb 17)
- Measuring Dystrophin in Dystrophinopathy Patients and Interpreting the Data; Public Scientific Workshops – 11454 (Mar 3)
- Neurological Devices Panel of the Medical Devices Advisory Committee – 9733 (Feb 24)
- Office of Regulatory Science and Innovation Science Symposium – 10700 (Feb 27)
- Orthopaedic and Rehabilitation Panel of the Medical Devices Advisory Committee – 8326 (Feb 17)
- Patient-Focused Drug Development for Functional Gastrointestinal Disorders – 7616 (Feb 11)
- Pediatric Advisory Committee – 11681 (Mar 4)
- Pediatric Ethics Subcommittee of the Pediatric Advisory Committee – 10123 (Feb 25)
- Pediatric Neurocognitive; Advancing the Development of Pediatric Therapeutics; Public Workshops – 11455 (Mar 3)
- Pediatric Stakeholder – 10493 (Feb 26)
- Pharmacy Compounding Advisory Committee – 3967 (Jan 26)
- PharmaLink Conference--Leadership in a Global Supply Chain – 4289 (Jan 27)
- Pulmonary-Allergy Drugs and the Drug Safety and Risk Management Advisory Committees – 7000 (Feb 9)
- Regulation of Combination Drug Medicated Feeds – 8092 (Feb 13)
- Robotically-Assisted Surgical Devices -- Challenges and Opportunities; Workshops – 10124 (Feb 25)
- The Tobacco Products Scientific Advisory Committee – 8093 (Feb 13)
- Toxicological Principles for the Safety Assessment of Food Ingredients – 5559 (Feb 2)
- Modifications to the List of Recognized Standards – 7617 (Feb 11)
- National Medical Device Postmarket Surveillance System Planning Board Report – 10125 (Feb 25)
- Partnership to Develop the Branded Food Products Database for Public Health (R01) – 9734 (Feb 24)
- Regulatory Site Visit Training Program – 8329 (Feb 17)
- Requests for Information:
- Public Health Concern Related to Racial/Ethnic Demographic Subgroups for Office of Minority Health Research – 10126 (Feb 25)
- Requests for Nominations:
- Food Advisory Committee; Closing Date Extension – 5559 (Feb 2)
 - Voting Members on a Public Advisory Committee; Science Board to the Food and Drug Administration – 3609 (Jan 23)
- User Fees:
- Generic Drug User Fee Amendments; Public Hearing on Policy Development; Reopening of Docket – 6729 (Feb 6)
- Withdrawal of Drug Products from Sale for Reasons other than Safety or Effectiveness:
- LYMPHAZURIN (Isosulfan Blue) Injectable, etc. – 5560 (Feb 2)